Home » Newsletters » BioWorld Science

BioWorld Science

May 26, 2020

View Archived Issues

Atherosclerosis, AD meet at the myelin

p53 loss leads to immune evasion

Karus Therapeutics initiates phase II study of KA-2507 in biliary tract cancer

Enrollment open in phase II study of MSTT-1041A or UTTR-1147A in COVID-19 pneumonia

Clinical data for novel non-D2-receptor-binding compound in patients with schizophrenia

DNA-encoded immunotherapies show efficacy in models of N. gonorrhoeae infection

First-in-human characterization of RPT-193

IRAK-2 is a therapeutic target in atopic dermatitis and psoriasis

AiCuris discovers HBV caspid assembly inhibitors

New SSAO inhibitors identified at Boehringer Ingelheim

Esteve patents voltage-dependent calcium channel subunit alpha2/delta-1 ligands

Merck & Co. identifies new LRRK2 inhibitors

New TYK2 inhibitors disclosed by Bristol-Myers Squibb

Germline ApoE variants affect melanoma trajectory

PEG10 found behind pathogenic mechanisms of mycosis fungoides

Phase III trial of efgartigimod in generalized myasthenia gravis meets primary endpoint

Chi-Med and BeiGene to study surufatinib and fruquintinib with tislelizumab for solid tumors

Synairgen's phase II trial begins dosing SNG-001 in home setting to treat COVID-19

Novartis begins phase II study of DFV-890 for COVID-19 pneumonia

Glenmark to begin phase III study of favipiravir with umifenovir in moderate COVID-19

Tavotek and Genmab partner to develop antibody for autoimmune and inflammatory conditions

Levels of cytokine LIGHT correlate with disease severity and mortality in COVID-19 ARDS study

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...